Preclinical and Early Development Capabilities

Target, Whole Cell, and Virtual Screening

• Compound libraries
  • DNA encoded
  • Natural products
  • Pharma partners
  • Patent
  • Other
• Target based
  • ID & validation
  • Crystallography
  • High and Medium throughput screening
• Whole Cell
  • Replicating, multiple C source, mutants
  • Non-replicating
  • Low pH
  • Macrophage
• Virtual
  • Docking
  • Ligand base
  • Phenotypic models

Lead Identification

• Hit Assessment
• Hit to Lead Medicinal Chemistry

Lead Optimization

• Medicinal Chemistry
• Animal Models
  • Acute/Chronic BalbC
  • Acute/Chronic C3HeB/FeJ
  • Marmoset
• Pharmacokinetics and Safety
  • Caseum penetration
  • Metabolomics
  • ADME, PK
  • In vitro/in vivo toxicology

Preclinical Development

• Lead(s) selected
  • Efficacy in advanced and/or combination models
  • In vitro tox
  • Non-GLP tox studies
  • Synergy/additivity/antagonism assessment
• Preclinical Candidate Selection
• Preclinical Candidate Profiling
  • IND enabling studies
  • CMC

Clinical

• Study design
• IND Preparation